Forest Laboratories Inc. is picking up rights to ceftaroline, a late-stage injectable antibiotic for Gram-positive bacterial infections, through the acquisition of privately held Cerexa Inc. for $480 million in a cash-for-stock transaction. (BioWorld Today)

Forest Laboratories Inc. is picking up rights to ceftaroline, a late-stage injectable antibiotic for Gram-positive bacterial infections, through the acquisition of privately held Cerexa Inc. for $480 million in a cash-for-stock transaction. (BioWorld Today)

In the latest example of big pharma turning to biotech to beef up its research and development pipelines, GlaxoSmithKline plc agreed to acquire Domantis Ltd. for £230 million (US$454 million) in cash. (BioWorld Today)

In the latest example of big pharma turning to biotech to beef up its research and development pipelines, GlaxoSmithKline plc agreed to acquire Domantis Ltd. for £230 million (US$454 million) in cash. (BioWorld Today)